Related Experiment Video
Updated: Mar 14, 2026
04:47
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
2.0K
Inhibition of Complement Retards Ankylosing Spondylitis Progression
Chaoqun Yang1,2, Peipei Ding3, Qingkai Wang3
1Department of Spine Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Scientific Reports
|October 5, 2016
Summary
Ankylosing spondylitis (AS) pathogenesis involves complement system activation. Inhibiting this system with Efb-C shows promise in reducing AS progression by affecting bone cells.
Area of Science:
- Immunology
- Rheumatology
- Osteoimmunology
Background:
- Ankylosing spondylitis (AS) is a chronic inflammatory disease causing spinal stiffness.
- Current treatments for AS are limited due to poorly understood disease mechanisms.
- The human leukocyte antigen B27 (HLA-B27) is a known genetic factor in AS.
Purpose of the Study:
- To investigate the role of the complement system in AS pathogenesis.
- To evaluate the therapeutic potential of complement inhibition in AS.
Main Methods:
- Utilized a proteoglycan (PG)-induced AS mouse model and human clinical specimens.
- Analyzed complement system activation in spinal bone marrow.
- Assessed changes in immune cell populations (neutrophils, macrophages) and serum TGF-β1 levels.
- Tested the efficacy of Staphylococcus aureus extracellular fibrinogen-binding protein C-terminal (Efb-C) as a complement inhibitor.
- Investigated the effects of complement activation on osteoblast and osteoclast cells in vitro.
Main Results:
- Complement system activation was significantly observed in the spinal bone marrow of AS mice.
- Alterations in neutrophil and macrophage proportions were noted in bone marrow and spleen.
- Serum levels of transforming growth factor-beta 1 (TGF-β1) were significantly increased.
- Efb-C treatment markedly slowed AS progression in mice by inhibiting osteoblast differentiation.
- Complement attack in vitro led to elevated TGF-β1 and RANKL in bone cells.
Conclusions:
- Complement system activation is closely implicated in the pathogenesis of ankylosing spondylitis.
- Targeting the complement system, potentially through inhibitors like Efb-C, represents a promising therapeutic strategy for AS.
- Understanding the interplay between complement, TGF-β1, and RANKL offers new avenues for AS treatment.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636
01:27Complement System
11.8K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
11.8K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
589
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
589
01:27Combined Effects of Drugs: Synergism
7.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
693
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
693
01:23Rheumatic Heart Disease I: Introduction
735
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
735